Cargando…

Tumor Progression Reverses Cardiac Hypertrophy and Fibrosis in a Tetracycline-Regulated ATF3 Transgenic Mouse Model

Cardiovascular diseases (CVD) and cancer are the top deadly diseases in the world. Both CVD and cancer have common risk factors; therefore, with the advances in treatment and life span, both diseases may occur simultaneously in patients. It is becoming evident that CVD and cancer are highly connecte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Awwad, Lama, Aronheim, Ami
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10528851/ https://www.ncbi.nlm.nih.gov/pubmed/37759510 http://dx.doi.org/10.3390/cells12182289

Ejemplares similares

Cardiac Dysfunction Promotes Cancer Progression via Multiple Secreted Factors
por: Awwad, Lama, et al.
Publicado: (2022)

Tumor Growth Ameliorates Cardiac Dysfunction and Suppresses Fibrosis in a Mouse Model for Duchenne Muscular Dystrophy
por: Achlaug, Laris, et al.
Publicado: (2023)

Tumor Growth Ameliorates Cardiac Dysfunction
por: Awwad, Lama, et al.
Publicado: (2023)

Adult Cardiac Expression of the Activating Transcription Factor 3, ATF3, Promotes Ventricular Hypertrophy
por: Koren, Lilach, et al.
Publicado: (2013)

Cardiac Remodeling in the Absence of Cardiac Contractile Dysfunction Is Sufficient to Promote Cancer Progression
por: Awwad, Lama, et al.
Publicado: (2022)

Correction: Adult Cardiac Expression of the Activating Transcription Factor 3, ATF3, Promotes Ventricular Hypertrophy
por: Koren, Lilach, et al.
Publicado: (2013)

JDP2 and ATF3 deficiencies dampen maladaptive cardiac remodeling and preserve cardiac function
por: Kalfon, Roy, et al.
Publicado: (2019)

ATF3 and JDP2 deficiency in cancer associated fibroblasts promotes tumor growth via SDF-1 transcription
por: Avraham, Shimrit, et al.
Publicado: (2019)

ATF3 expression in cardiomyocytes and myofibroblasts following transverse aortic constriction displays distinct phenotypes
por: Soraya, Abu-Sharki, et al.
Publicado: (2020)

The ubiquitously expressed bZIP inhibitor, JDP2, suppresses the transcription of its homologue immediate early gene counterpart, ATF3
por: Weidenfeld-Baranboim, Keren, et al.
Publicado: (2009)

Reversibility and progression in conditional transgenic mouse models of breast cancer
por: Chodosh, LA, et al.
Publicado: (2003)

Sensory ataxia and cardiac hypertrophy caused by neurovascular oxidative stress in chemogenetic transgenic mouse lines
por: Yadav, Shambhu, et al.
Publicado: (2023)

Brain-wide distribution of reporter expression in five transgenic tetracycline-transactivator mouse lines
por: Lillehaug, Sveinung, et al.
Publicado: (2019)

Porcine model of progressive cardiac hypertrophy and fibrosis with secondary postcapillary pulmonary hypertension
por: Gyöngyösi, Mariann, et al.
Publicado: (2017)

Identification of circular RNAs in cardiac hypertrophy and cardiac fibrosis
por: Chen, Yan, et al.
Publicado: (2022)

A novel tetracycline-responsive transgenic mouse strain for skeletal muscle-specific gene expression
por: Iwata, Masahiro, et al.
Publicado: (2018)

Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat
por: Leader, Catherine J., et al.
Publicado: (2020)

Transgenic mouse model for imaging of ATF4 translational activation-related cellular stress responses in vivo
por: Iwawaki, Takao, et al.
Publicado: (2017)

Human Relaxin‐2 Fusion Protein Treatment Prevents and Reverses Isoproterenol‐Induced Hypertrophy and Fibrosis in Mouse Heart
por: Sun, Junhui, et al.
Publicado: (2019)

A transgenic mouse line for collecting ribosome-bound mRNA using the tetracycline transactivator system
por: Drane, Laurel, et al.
Publicado: (2014)

Overview of MicroRNAs in Cardiac Hypertrophy, Fibrosis, and Apoptosis
por: Wang, Juan, et al.
Publicado: (2016)

Progression of Hypertrophy and Myocardial Fibrosis in Aortic Stenosis: A Multicenter Cardiac Magnetic Resonance Study
por: Everett, Russell J., et al.
Publicado: (2018)

A new transgenic mouse line for tetracycline inducible transgene expression in mature melanocytes and the melanocyte stem cells using the Dopachrome tautomerase promoter
por: Woods, Susan L., et al.
Publicado: (2010)

Mouse models for the study of postnatal cardiac hypertrophy
por: Del Olmo-Turrubiarte, A., et al.
Publicado: (2015)

Progression and regression of left ventricular hypertrophy and myocardial fibrosis in a mouse model of hypertension and concomitant cardiomyopathy
por: Kwiecinski, Jacek, et al.
Publicado: (2020)

Tetracycline-controlled transgene activation using the ROSA26-iM2-GFP knock-in mouse strain permits GFP monitoring of DOX-regulated transgene-expression
por: Wörtge, Simone, et al.
Publicado: (2010)

The ER Unfolded Protein Response Effector, ATF6, Reduces Cardiac Fibrosis and Decreases Activation of Cardiac Fibroblasts
por: Stauffer, Winston T., et al.
Publicado: (2020)

MicroRNA-327 regulates cardiac hypertrophy and fibrosis induced by pressure overload
por: Ji, Yue, et al.
Publicado: (2018)

Tetracycline Treatment Retards the Onset and Slows the Progression of Diabetes in Human Amylin/Islet Amyloid Polypeptide Transgenic Mice
por: Aitken, Jacqueline F., et al.
Publicado: (2010)

Bezafibrate Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis
por: Xu, Si-Chi, et al.
Publicado: (2017)

FIAT represses ATF4-mediated transcription to regulate bone mass in transgenic mice
por: Yu, Vionnie W.C., et al.
Publicado: (2005)

Cardiac Expression of Factor X Mediates Cardiac Hypertrophy and Fibrosis in Pressure Overload
por: Guo, Xinji, et al.
Publicado: (2020)

Cardiac Expression of Factor X Mediates Cardiac Hypertrophy and Fibrosis in Pressure Overload
Publicado: (2022)

TNNI3K, a Cardiac-Specific Kinase, Promotes Physiological Cardiac Hypertrophy in Transgenic Mice
por: Wang, Xiaojian, et al.
Publicado: (2013)

Inhalation of diesel exhaust does not exacerbate cardiac hypertrophy or heart failure in two mouse models of cardiac hypertrophy
por: Liu, Yonggang, et al.
Publicado: (2013)

Reversible cardiac hypertrophy induced by PEG-coated gold nanoparticles in mice
por: Yang, Chengzhi, et al.
Publicado: (2016)

Targeting miR-30d reverses pathological cardiac hypertrophy
por: Li, Jin, et al.
Publicado: (2022)

Reversing Cardiac Hypertrophy at the Source Using a Cardiac Targeting Peptide Linked to miRNA106a: Targeting Genes That Cause Cardiac Hypertrophy
por: Gallicano, G. Ian, et al.
Publicado: (2022)

IKKi Deficiency Promotes Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis
por: Dai, Jia, et al.
Publicado: (2013)

Overlapping and differential functions of ATF6α versus ATF6β in the mouse heart
por: Correll, Robert N., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_74qhu5v1nennarh26q6kmafqs5